#1 Clinical Trials Search in Europe

Tasquinimod

Tasquinimod, an experimental drug, is being studied in various clinical trials for its potential in treating different types of cancer. These trials aim to evaluate the safety, efficacy, and optimal dosing of tasquinimod, both as a single agent and in combination with other treatments. The studies focus on cancers such as prostate cancer, multiple myeloma, and myelofibrosis, offering hope for patients with advanced or treatment-resistant forms of these diseases.

Table of Contents

What is Tasquinimod?

Tasquinimod, also known as ABR-215050, is an experimental drug that has shown promise in treating various types of cancer[1]. It is a quinoline-3-carboxamide analog, which is a type of chemical compound that has demonstrated anti-cancer properties[2]. Tasquinimod is currently being studied for its potential to slow down or stop the growth of cancer cells and improve outcomes for patients with different types of cancer.

What Conditions Does Tasquinimod Treat?

Tasquinimod is being investigated for the treatment of several types of cancer, including:

  • Prostate Cancer: Particularly in patients with metastatic castration-resistant prostate cancer (mCRPC), which is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy[3][4]
  • Hepatocellular Carcinoma: A type of liver cancer[1]
  • Ovarian Cancer[1]
  • Renal Cell Carcinoma: A type of kidney cancer[1]
  • Gastric Cancer: Cancer of the stomach[1]
  • Multiple Myeloma: A type of blood cancer that affects plasma cells[5]
  • Myelofibrosis: A rare type of blood cancer that affects bone marrow[6]

How Does Tasquinimod Work?

Tasquinimod works by targeting specific processes in cancer cells and their environment. While the exact mechanism is still being studied, researchers believe it may work in the following ways:

  • Inhibiting S100A9: Tasquinimod is known to inhibit a protein called S100A9, which is involved in cancer growth and spread[5]
  • Anti-angiogenic effects: It may help prevent the formation of new blood vessels that feed tumors, a process called angiogenesis[3]
  • Modulating the tumor microenvironment: Tasquinimod might affect the area surrounding cancer cells, making it less favorable for cancer growth[3]

Clinical Trials and Research

Tasquinimod has been studied in various clinical trials, ranging from early Phase 1 studies to larger Phase 3 trials. Some key findings include:

  • Prostate Cancer: A Phase 3 study showed that tasquinimod improved radiographic progression-free survival in patients with metastatic prostate cancer[5]
  • Multiple Cancers: A Phase 2 study investigated tasquinimod in patients with advanced hepatocellular, ovarian, renal cell, and gastric cancers[1]
  • Myelofibrosis: Ongoing studies are exploring tasquinimod’s potential in patients with myelofibrosis who have not responded well to other treatments[6]
  • Combination Therapies: Researchers are studying tasquinimod in combination with other cancer treatments, such as chemotherapy drugs and radiation therapy[2][7]

How is Tasquinimod Administered?

Tasquinimod is typically administered as an oral medication in the form of capsules. The dosing schedule may vary depending on the specific study or treatment plan, but generally includes:

  • Starting dose: Often begins at 0.25 mg or 0.5 mg per day[1]
  • Dose escalation: The dose may be increased gradually to 1 mg per day, depending on how well the patient tolerates the medication[1]
  • Continuous dosing: Tasquinimod is usually taken once daily with water and food[8]

Potential Side Effects

As with any medication, tasquinimod may cause side effects. Common side effects reported in clinical trials include:

  • Fatigue
  • Nausea
  • Decreased appetite
  • Muscle pain
  • Anemia (low red blood cell count)

It’s important to note that the full range of side effects is still being studied, and patients should discuss potential risks with their healthcare provider[8].

Future Research and Potential

Tasquinimod continues to be studied in various clinical trials to better understand its effectiveness and safety profile. Ongoing research is exploring:

  • Combination therapies: Testing tasquinimod with other cancer treatments to potentially enhance effectiveness[5]
  • Expanded use: Investigating its potential in treating additional types of cancer[6]
  • Biomarkers: Identifying specific markers that might predict which patients are most likely to benefit from tasquinimod treatment[2]

While tasquinimod shows promise, it’s important to remember that it is still an experimental drug. Patients interested in tasquinimod should discuss their options with their oncologist and consider participating in clinical trials if appropriate.

Aspect Details
Cancer Types Studied Prostate cancer, Multiple myeloma, Myelofibrosis, Hepatocellular carcinoma, Ovarian cancer, Renal cell carcinoma, Gastric cancer
Administration Oral capsules, typically 0.25 mg to 1 mg daily
Primary Objectives Safety profile, Optimal dosing, Efficacy (Progression-free survival, Overall survival)
Combination Therapies With ruxolitinib (for myelofibrosis), With ixazomib, lenalidomide, and dexamethasone (for multiple myeloma)
Key Endpoints Progression-free survival, Overall survival, Quality of life, Bone-specific alkaline phosphatase response, Time to skeletal-related events
Safety Monitoring Adverse events, Blood cell counts, Liver function, General tolerability
Patient Populations Often includes patients with advanced or treatment-resistant cancers

FAQ

  • What types of cancer is tasquinimod being studied for? Tasquinimod is being studied for various types of cancer, including prostate cancer, multiple myeloma, myelofibrosis, hepatocellular carcinoma, ovarian cancer, renal cell carcinoma, and gastric cancer.
  • How is tasquinimod administered in clinical trials? Tasquinimod is typically administered orally as a capsule, with dosages ranging from 0.25 mg to 1 mg per day, depending on the specific trial and patient tolerability.
  • What are the main objectives of tasquinimod clinical trials? The main objectives include determining the safety profile, optimal dosing, and efficacy of tasquinimod. Trials aim to assess its impact on progression-free survival, overall survival, and quality of life in cancer patients.
  • Are there any combination therapies being tested with tasquinimod? Yes, some trials are exploring tasquinimod in combination with other treatments. For example, it's being studied with ruxolitinib for myelofibrosis, and with ixazomib, lenalidomide, and dexamethasone for multiple myeloma.
  • What are some potential side effects of tasquinimod? While specific side effects can vary, clinical trials closely monitor for adverse events. Common areas of focus include changes in blood cell counts, liver function, and general tolerability. Detailed safety profiles are being established through these studies.

Ongoing Clinical Trials on Tasquinimod

  • Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands

Glossary

  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC): A type of prostate cancer that has spread beyond the prostate and continues to grow despite treatments that lower testosterone levels.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Myelofibrosis: A rare type of blood cancer where the bone marrow is replaced by scar tissue, affecting normal blood cell production.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to carry out daily activities while dealing with a disease and its treatment.
  • Bone-Specific Alkaline Phosphatase (bone-ALP): An enzyme in the blood that can indicate increased bone cell activity, often used as a marker in cancer that has spread to the bones.
  • Skeletal-Related Event (SRE): Complications that can occur when cancer spreads to the bones, such as fractures or the need for radiation therapy to relieve bone pain.

References

  1. https://clinicaltrials.gov/study/NCT01743469
  2. https://clinicaltrials.gov/study/NCT02396368
  3. https://clinicaltrials.gov/study/NCT01234311
  4. https://clinicaltrials.gov/study/NCT02057666
  5. https://clinicaltrials.gov/study/NCT04405167
  6. https://clinicaltrials.eu/trial/study-on-tasquinimod-for-patients-with-myelofibrosis-who-are-refractory-or-intolerant-to-jak2-inhibitors/
  7. https://clinicaltrials.gov/study/NCT01513733
  8. https://clinicaltrials.gov/study/NCT01732549